1. Academic Validation
  2. BLU-285, DCC-2618 Show Activity against GIST

BLU-285, DCC-2618 Show Activity against GIST

  • Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.CD-NB2016-165.
Abstract

Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease progression due to activation loop mutations, which are resistant to approved drugs. However, phase I trials suggest that the Cancer is sensitive to two new agents: BLU-285 and DCC-2618. In addition, liquid biopsies, which were used to follow patients during the trials, may be valuable tools in tracking disease progression and assessing tumor heterogeneity.

Figures
Products